{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:23:46Z","timestamp":1788927826776,"version":"build-2803163510"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00210-025-03898-2","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T05:47:36Z","timestamp":1740030456000},"page":"8091-8110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploring the therapeutic potential of natural products in modulating miRNA networks in prostate cancer"],"prefix":"10.1007","volume":"398","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9712-9609","authenticated-orcid":false,"given":"Osama A.","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"3898_CR1","doi-asserted-by":"crossref","unstructured":"Adekiya TA, Owoseni O (2023) Emerging frontiers in nanomedicine targeted therapy for prostate cancer. Cancer Treat Res Commun 100778","DOI":"10.1016\/j.ctarc.2023.100778"},{"key":"3898_CR2","doi-asserted-by":"crossref","unstructured":"Amare DE (2020) Anti-cancer and other biological effects of a dietary compound 3, 3\u2032-diindolylmethane supplementation: a systematic review of human clinical trials. Nutri Dietary Suppl 123\u2013137","DOI":"10.2147\/NDS.S261577"},{"key":"3898_CR3","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.1007\/s11033-021-06575-8","volume":"48","author":"K Anjaly","year":"2021","unstructured":"Anjaly K, Tiku A (2021) MicroRNA mediated therapeutic effects of natural agents in prostate cancer. Mol Biol Rep 48:5759\u20135773","journal-title":"Mol Biol Rep"},{"key":"3898_CR4","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.3390\/cells12182207","volume":"12","author":"L Armstrong","year":"2023","unstructured":"Armstrong L, Willoughby CE, McKenna DJ (2023) Targeting of AKT1 by miR-143-3p suppresses epithelial-to-mesenchymal transition in prostate cancer. Cells 12:2207","journal-title":"Cells"},{"key":"3898_CR5","first-page":"1","volume":"11","author":"JK Badawi","year":"2023","unstructured":"Badawi JK (2023) Resveratrol used as nanotherapeutic: a promising additional therapeutic tool against hormone-sensitive, hormone-insensitive and resistant prostate cancer. Am J Clin Exp Urol 11:1","journal-title":"Am J Clin Exp Urol"},{"key":"3898_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, Bray F, Brawley O, Luckenbaugh AN, Mucci L (2023) 2022 update on prostate cancer epidemiology and risk factors\u2014a systematic review. Eur Urol 84:191\u2013206","journal-title":"Eur Urol"},{"key":"3898_CR7","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.3390\/cancers14215418","volume":"14","author":"E Bevacqua","year":"2022","unstructured":"Bevacqua E, Ammirato S, Cione E, Curcio R, Dolce V, Tucci P (2022) The potential of microRNAs as non-invasive prostate cancer biomarkers: a systematic literature review based on a machine learning approach. Cancers 14:5418","journal-title":"Cancers"},{"key":"3898_CR8","doi-asserted-by":"publisher","first-page":"272","DOI":"10.7150\/ijbs.2929","volume":"8","author":"G Chen","year":"2012","unstructured":"Chen G, Deng C, Li Y-P (2012) TGF-\u03b2 and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci 8:272","journal-title":"Int J Biol Sci"},{"key":"3898_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3892\/ijo.2017.4038","volume":"51","author":"W Chen","year":"2017","unstructured":"Chen W, Liu Y, Chen H, Ning H, Ding K (2017) Loss of miR-449a-caused PrLZ overexpression promotes prostate cancer metastasis. Int J Oncol 51:435\u2013444","journal-title":"Int J Oncol"},{"key":"3898_CR10","doi-asserted-by":"publisher","first-page":"e70372","DOI":"10.1371\/journal.pone.0070372","volume":"8","author":"T Chiyomaru","year":"2013","unstructured":"Chiyomaru T, Yamamura S, Fukuhara S, Yoshino H, Kinoshita T, Majid S, Saini S, Chang I, Tanaka Y, Enokida H (2013) Genistein inhibits prostate cancer cell growth by targeting miR-34a and oncogenic HOTAIR. PLoS ONE 8:e70372","journal-title":"PLoS ONE"},{"issue":"8","key":"3898_CR11","doi-asserted-by":"publisher","first-page":"e43812","DOI":"10.1371\/journal.pone.0043812","volume":"7","author":"T Chiyomaru","year":"2012","unstructured":"Chiyomaru T, Yamamura S, Zaman MS, Majid S, Deng G, Shahryari V, Saini S, Hirata H, Ueno K, Chang I (2012) Genistein suppresses prostate cancer growth through inhibition of oncogenic microRNA-151. PLOS ONE 7(8):e43812","journal-title":"PLOS ONE"},{"key":"3898_CR12","doi-asserted-by":"publisher","first-page":"1395244","DOI":"10.3389\/fonc.2024.1395244","volume":"14","author":"S Choi","year":"2024","unstructured":"Choi S, Lee S, Han Y-H, Choi J, Kim I, Lee J, An H-J (2024) Corrigendum: miR-31-3p functions as a tumor suppressor by directly targeting GABBR2 in prostate cancer. Front Oncol 14:1395244","journal-title":"Front Oncol"},{"key":"3898_CR13","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.3390\/cancers15164148","volume":"15","author":"M Cruz-Burgos","year":"2023","unstructured":"Cruz-Burgos M, Cort\u00e9s-Ram\u00edrez SA, Losada-Garc\u00eda A, Morales-Pacheco M, Mart\u00ednez-Mart\u00ednez E, Morales-Montor JG, Serv\u00edn-Haddad A, Izquierdo-Luna JS, Rodr\u00edguez-Mart\u00ednez G, Ramos-God\u00ednez MdP (2023) Unraveling the role of EV-derived miR-150-5p in prostate cancer metastasis and its association with high-grade Gleason scores: implications for diagnosis. Cancers 15:4148","journal-title":"Cancers"},{"key":"3898_CR14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrc1840","volume":"6","author":"A Esquela-Kerscher","year":"2006","unstructured":"Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6:259\u2013269","journal-title":"Nat Rev Cancer"},{"key":"3898_CR15","first-page":"3755","volume":"20","author":"L Fan","year":"2019","unstructured":"Fan L, Wang Y, Huo W, Wang W-H (2019) MicroRNA-301a-3p overexpression promotes cell invasion and proliferation by targeting runt-related transcription factor 3 in prostate cancer. Mol Med Rep 20:3755\u20133763","journal-title":"Mol Med Rep"},{"key":"3898_CR16","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3390\/cancers11040478","volume":"11","author":"AA Farooqi","year":"2019","unstructured":"Farooqi AA, Qureshi MZ, Khalid S, Attar R, Martinelli C, Sabitaliyevich UY, Nurmurzayevich SB, Taverna S, Poltronieri P, Xu B (2019) Regulation of cell signaling pathways by berberine in different cancers: searching for missing pieces of an incomplete jig-saw puzzle for an effective cancer therapy. Cancers 11:478","journal-title":"Cancers"},{"key":"3898_CR17","first-page":"6943","volume":"14","author":"S Feng","year":"2017","unstructured":"Feng S, Qian X, Li H, Zhang X (2017) Combinations of elevated tissue miRNA-17-92 cluster expression and serum prostate-specific antigen as potential diagnostic biomarkers for prostate cancer. Oncol Lett 14:6943\u20136949","journal-title":"Oncol Lett"},{"key":"3898_CR18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3892\/br.2016.747","volume":"5","author":"Y-H Feng","year":"2016","unstructured":"Feng Y-H, Tsao C-J (2016) Emerging role of microRNA-21 in cancer. Biomedical Reports 5:395\u2013402","journal-title":"Biomedical Reports"},{"key":"3898_CR19","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.7150\/jca.78246","volume":"13","author":"Y Feng","year":"2022","unstructured":"Feng Y, Cao H, Zhao W, Chen L, Wang D, Gao R (2022) miR-143 mediates abiraterone acetate resistance by regulating the JNK\/Bcl-2 signaling pathway in prostate cancer. J Cancer 13:3652","journal-title":"J Cancer"},{"key":"3898_CR20","doi-asserted-by":"publisher","first-page":"1437951","DOI":"10.3389\/fcell.2024.1437951","volume":"12","author":"L Gan","year":"2024","unstructured":"Gan L, Zheng L, Zou J, Luo P, Chen T, Zou J, Li W, Chen Q, Cheng L, Zhang F (2024) MicroRNA-21 in urologic cancers: from molecular mechanisms to clinical implications. Front Cell Dev Biol 12:1437951","journal-title":"Front Cell Dev Biol"},{"key":"3898_CR21","doi-asserted-by":"publisher","first-page":"7748","DOI":"10.18632\/oncotarget.2294","volume":"5","author":"Y Goto","year":"2014","unstructured":"Goto Y, Kojima S, Nishikawa R, Enokida H, Chiyomaru T, Kinoshita T, Nakagawa M, Naya Y, Ichikawa T, Seki N (2014) The microRNA-23b\/27b\/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer. Oncotarget 5:7748","journal-title":"Oncotarget"},{"key":"3898_CR22","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1080\/15384047.2019.1599659","volume":"20","author":"C Guan","year":"2019","unstructured":"Guan C, Zhang L, Wang S, Long L, Zhou H, Qian S, Ma M, Bai F, Meng QH, Lyu J (2019) Upregulation of MicroRNA-21 promotes tumorigenesis of prostate cancer cells by targeting KLF5. Cancer Biol Ther 20:1149\u20131161","journal-title":"Cancer Biol Ther"},{"key":"3898_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/16833_2024_475","volume-title":"Correction to: MicroRNA: exploring their multifaceted role in cancer","author":"NM Hamdy","year":"2024","unstructured":"Hamdy NM, Doghish AS, El-Husseiny AA, Fathi D, Rizk NI, Abdelmaksoud NM, Abulsoud AI (2024) Correction to: MicroRNA: exploring their multifaceted role in cancer. Springer"},{"key":"3898_CR24","doi-asserted-by":"crossref","unstructured":"Han K, Meng W, Zhang J-j, Zhou Y, Wang Y-l, Su Y, Lin S-c, Gan Z-h, Sun Y-n, Min D-l (2016) Luteolin inhibited proliferation and induced apoptosis of prostate cancer cells through miR-301. OncoTargets Ther 3085\u20133094","DOI":"10.2147\/OTT.S102862"},{"key":"3898_CR25","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/bjc.2014.48","volume":"110","author":"H Hirata","year":"2014","unstructured":"Hirata H, Hinoda Y, Shahryari V, Deng G, Tanaka Y, Tabatabai Z, Dahiya R (2014) Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells. Br J Cancer 110:1645\u20131654","journal-title":"Br J Cancer"},{"key":"3898_CR26","doi-asserted-by":"publisher","first-page":"1065757","DOI":"10.3389\/fgene.2023.1065757","volume":"14","author":"G Jain","year":"2023","unstructured":"Jain G, Das P, Ranjan P, Neha VF, Cieza-Borrella C (2023) Urinary extracellular vesicles miRNA\u2014A new era of prostate cancer biomarkers. Front Genet 14:1065757","journal-title":"Front Genet"},{"key":"3898_CR27","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA, Trujillo B, Al-Lazikani B, Attard G, Bray F (2024) The lancet commission on prostate cancer: planning for the surge in cases. The Lancet 403:1683\u20131722","journal-title":"The Lancet"},{"key":"3898_CR28","doi-asserted-by":"publisher","first-page":"613464","DOI":"10.3389\/fphar.2020.613464","volume":"11","author":"Z Javed","year":"2021","unstructured":"Javed Z, Khan K, Rasheed A, Sadia H, Raza S, Salehi B, Cho WC, Sharifi-Rad J, Koch W, Kukula-Koch W (2021) MicroRNAs and natural compounds mediated regulation of TGF signaling in prostate cancer. Front Pharmacol 11:613464","journal-title":"Front Pharmacol"},{"key":"3898_CR29","doi-asserted-by":"publisher","first-page":"5167829","DOI":"10.1155\/2018\/5167829","volume":"2018","author":"L-h Jiang","year":"2018","unstructured":"Jiang L-h, Zhang H-d, Tang J-h (2018) MiR-30a: a novel biomarker and potential therapeutic target for cancer. J Oncol 2018:5167829","journal-title":"J Oncol"},{"key":"3898_CR30","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.3390\/molecules28135246","volume":"28","author":"M Kciuk","year":"2023","unstructured":"Kciuk M, Alam M, Ali N, Rashid S, G\u0142owacka P, Sundaraj R, Celik I, Yahya EB, Dubey A, Zerroug E (2023) Epigallocatechin-3-gallate therapeutic potential in cancer: mechanism of action and clinical implications. Molecules 28:5246","journal-title":"Molecules"},{"key":"3898_CR31","doi-asserted-by":"crossref","unstructured":"Khan MS, Fatima M, Gupta G, Md S, Kesharwani P (2024a) Recent progress in Zein nanoparticles: a promising approach for advancing Cancer therapy. J Drug Del Sci Technol 105770","DOI":"10.1016\/j.jddst.2024.105770"},{"key":"3898_CR32","doi-asserted-by":"crossref","unstructured":"Khan MS, Gowda BJ, Hasan N, Gupta G, Singh T, Md S, Kesharwani P (2024b) Carbon nanotube-mediated platinum-based drug delivery for the treatment of cancer: advancements and future perspectives. Eur Polyme J 112800","DOI":"10.1016\/j.eurpolymj.2024.112800"},{"key":"3898_CR33","doi-asserted-by":"crossref","unstructured":"Khan MS, Gupta G, Alsayari A, Wahab S, Sahebkar A, Kesharwani P (2024c) Advancements in liposomal formulations: a comprehensive exploration of industrial production techniques. Intl J Pharmaceut 124212","DOI":"10.1016\/j.ijpharm.2024.124212"},{"key":"3898_CR34","doi-asserted-by":"crossref","unstructured":"Kolluru V, Chandrasekaran B, Tyagi A, Dervishi A, Ankem M, Yan X, Maiying K, Alatassi H, Shaheen SP, Messer JC (2018) miR-301a expression: diagnostic and prognostic marker for prostate cancer. Urologic oncology: seminars and original investigations. Elsevier, pp. 503. e509\u2013503. e515","DOI":"10.1016\/j.urolonc.2018.07.014"},{"key":"3898_CR35","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.ctrv.2013.10.005","volume":"40","author":"J Kroon","year":"2014","unstructured":"Kroon J, Metselaar JM, Storm G, van der Pluijm G (2014) Liposomal nanomedicines in the treatment of prostate cancer. Cancer Treat Rev 40:578\u2013584","journal-title":"Cancer Treat Rev"},{"key":"3898_CR36","doi-asserted-by":"publisher","first-page":"559","DOI":"10.4103\/1008-682X.177839","volume":"18","author":"B Kumar","year":"2016","unstructured":"Kumar B, Lupold SE (2016) MicroRNA expression and function in prostate cancer: a review of current knowledge and opportunities for discovery. Asian J Androl 18:559\u2013567","journal-title":"Asian J Androl"},{"key":"3898_CR37","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41419-024-07133-3","volume":"15","author":"M Labb\u00e9","year":"2024","unstructured":"Labb\u00e9 M, Chang M, Saintpierre B, Letourneur F, de Beaurepaire L, V\u00e9ziers J, Deshayes S, Cotinat M, Fonteneau J-F, Blanquart C (2024) Loss of miR-200c-3p promotes resistance to radiation therapy via the DNA repair pathway in prostate cancer. Cell Death Dis 15:751","journal-title":"Cell Death Dis"},{"key":"3898_CR38","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1038\/onc.2009.192","volume":"28","author":"K-H Lee","year":"2009","unstructured":"Lee K-H, Chen Y-L, Yeh S, Hsiao M, Lin J, Goan Y, Lu P-J (2009) MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene 28:3360\u20133370","journal-title":"Oncogene"},{"key":"3898_CR39","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jconrel.2019.10.007","volume":"313","author":"SWL Lee","year":"2019","unstructured":"Lee SWL, Paoletti C, Campisi M, Osaki T, Adriani G, Kamm RD, Mattu C, Chiono V (2019) MicroRNA delivery through nanoparticles. J Control Release 313:80\u201395","journal-title":"J Control Release"},{"key":"3898_CR40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/ncrna8010010","volume":"8","author":"AL Leit\u00e3o","year":"2022","unstructured":"Leit\u00e3o AL, Enguita FJ (2022) A structural view of miRNA biogenesis and function. Non-Coding RNA 8:10","journal-title":"Non-Coding RNA"},{"key":"3898_CR41","doi-asserted-by":"publisher","first-page":"640587","DOI":"10.3389\/fcell.2021.640587","volume":"9","author":"W Li","year":"2021","unstructured":"Li W, Wang Y, Liu R, Kasinski AL, Shen H, Slack FJ, Tang DG (2021) MicroRNA-34a: potent tumor suppressor, cancer stem cell inhibitor, and potential anticancer therapeutic. Front Cell Dev Biol 9:640587","journal-title":"Front Cell Dev Biol"},{"key":"3898_CR42","doi-asserted-by":"crossref","unstructured":"Li Y, Zhang L, Dong Z, Xu H, Yan L, Yang S, Chen T, Chen S-l, Wang W, Yang Q, Chen C (2020) MicroRNA-155\u20135p promotes tumor progression and contributes paclitaxel resistance to chemotherapy via TP53INP1 in human Breast Cancer","DOI":"10.21203\/rs.3.rs-16886\/v1"},{"key":"3898_CR43","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1158\/0008-5472.CAN-11-3864","volume":"72","author":"C Liu","year":"2012","unstructured":"Liu C, Kelnar K, Vlassov AV, Brown D, Wang J, Tang DG (2012) Distinct microRNA expression profiles in prostate cancer stem\/progenitor cells and tumor-suppressive functions of let-7. Can Res 72:3393\u20133404","journal-title":"Can Res"},{"key":"3898_CR44","first-page":"20","volume":"42","author":"Y Liu","year":"2019","unstructured":"Liu Y, Sun H, Makabel B, Cui Q, Li J, Su C, Ashby CR Jr, Chen Z, Zhang J (2019) The targeting of non-coding RNAs by curcumin: facts and hopes for cancer therapy. Oncol Rep 42:20\u201334","journal-title":"Oncol Rep"},{"key":"3898_CR45","first-page":"5971","volume":"15","author":"Y L\u00fc","year":"2018","unstructured":"L\u00fc Y, Han B, Yu H, Cui Z, Li Z, Wang J (2018) Berberine regulates the microRNA-21-ITG\u03924-PDCD4 axis and inhibits colon cancer viability. Oncol Lett 15:5971\u20135976","journal-title":"Oncol Lett"},{"key":"3898_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12894-017-0206-6","volume":"17","author":"HN Luu","year":"2017","unstructured":"Luu HN, Lin H-Y, S\u00f8rensen KD, Ogunwobi OO, Kumar N, Chornokur G, Phelan C, Jones D, Kidd L, Batra J (2017) miRNAs associated with prostate cancer risk and progression. BMC Urol 17:1\u201318","journal-title":"BMC Urol"},{"key":"3898_CR47","doi-asserted-by":"publisher","first-page":"6435","DOI":"10.1158\/0008-5472.CAN-12-2181","volume":"72","author":"S Majid","year":"2012","unstructured":"Majid S, Dar AA, Saini S, Arora S, Shahryari V, Zaman MS, Chang I, Yamamura S, Tanaka Y, Deng G (2012) miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Can Res 72:6435\u20136446","journal-title":"Can Res"},{"key":"3898_CR48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1158\/1078-0432.CCR-12-2952","volume":"19","author":"S Majid","year":"2013","unstructured":"Majid S, Dar AA, Saini S, Shahryari V, Arora S, Zaman MS, Chang I, Yamamura S, Tanaka Y, Chiyomaru T (2013) miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin Cancer Res 19:73\u201384","journal-title":"Clin Cancer Res"},{"key":"3898_CR49","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.1007\/s13277-015-4336-8","volume":"37","author":"A Mao","year":"2016","unstructured":"Mao A, Liu Y, Wang Y, Zhao Q, Zhou X, Sun C, Di C, Si J, Gan L, Zhang H (2016) miR-449a enhances radiosensitivity through modulating pRb\/E2F1 in prostate cancer cells. Tumor Biol 37:4831\u20134840","journal-title":"Tumor Biol"},{"key":"3898_CR50","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3892\/or.2013.2452","volume":"30","author":"Y Mao","year":"2013","unstructured":"Mao Y, Chen H, Lin Y, Xu X, Hu Z, Zhu Y, Wu J, Xu X, Zheng X, Xie L (2013) microRNA-330 inhibits cell motility by downregulating Sp1 in prostate cancer cells. Oncol Rep 30:327\u2013333","journal-title":"Oncol Rep"},{"key":"3898_CR51","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/molecules24010193","volume":"24","author":"Y Miyata","year":"2019","unstructured":"Miyata Y, Shida Y, Hakariya T, Sakai H (2019) Anti-cancer effects of green tea polyphenols against prostate cancer. Molecules 24:193","journal-title":"Molecules"},{"key":"3898_CR52","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/ptr.8107","volume":"38","author":"A Mondal","year":"2024","unstructured":"Mondal A, Banerjee S, Terang W, Bishayee A, Zhang J, Ren L, da Silva MN, Bishayee A (2024) Capsaicin: a chili pepper bioactive phytocompound with a potential role in suppressing cancer development and progression. Phytother Res 38:1191\u20131223","journal-title":"Phytother Res"},{"key":"3898_CR53","doi-asserted-by":"publisher","first-page":"8367","DOI":"10.3390\/molecules27238367","volume":"27","author":"A Naeem","year":"2022","unstructured":"Naeem A, Hu P, Yang M, Zhang J, Liu Y, Zhu W, Zheng Q (2022) Natural products as anticancer agents: current status and future perspectives. Molecules 27:8367","journal-title":"Molecules"},{"key":"3898_CR54","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1080\/10942912.2023.2281257","volume":"26","author":"H Naeem","year":"2023","unstructured":"Naeem H, Momal U, Imran M, Shahbaz M, Hussain M, Alsagaby SA, Al Abdulmonem W, Umar M, Mujtaba A, El-Ghorab AH (2023) Anticancer perspectives of genistein: a comprehensive review. Int J Food Prop 26:3305\u20133341","journal-title":"Int J Food Prop"},{"key":"3898_CR55","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/carcin\/bgz193","volume":"41","author":"A Naiki-Ito","year":"2020","unstructured":"Naiki-Ito A, Naiki T, Kato H, Iida K, Etani T, Nagayasu Y, Suzuki S, Yamashita Y, Inaguma S, Onishi M (2020) Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer. Carcinogenesis 41:1145\u20131157","journal-title":"Carcinogenesis"},{"key":"3898_CR56","doi-asserted-by":"publisher","first-page":"1049888","DOI":"10.3389\/fonc.2022.1049888","volume":"12","author":"Y Nan","year":"2023","unstructured":"Nan Y, Su H, Zhou B, Liu S (2023) The function of natural compounds in important anticancer mechanisms. Front Oncol 12:1049888","journal-title":"Front Oncol"},{"key":"3898_CR57","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/onc.2009.19","volume":"28","author":"E Noonan","year":"2009","unstructured":"Noonan E, Place R, Pookot D, Basak S, Whitson J, Hirata H, Giardina C, Dahiya R (2009) miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 28:1714\u20131724","journal-title":"Oncogene"},{"key":"3898_CR58","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3892\/ijo.2017.4008","volume":"51","author":"A Okato","year":"2017","unstructured":"Okato A, Arai T, Kojima S, Koshizuka K, Osako Y, Idichi T, Kurozumi A, Goto Y, Kato M, Naya Y (2017) Dual strands of pre-miR-150 (miR-150-5p and miR-150-3p) act as antitumor miRNAs targeting SPOCK1 in na\u00efve and castration-resistant prostate cancer. Int J Oncol 51:245\u2013256","journal-title":"Int J Oncol"},{"key":"3898_CR59","doi-asserted-by":"publisher","first-page":"116165","DOI":"10.1016\/j.biopha.2024.116165","volume":"171","author":"K Otmani","year":"2024","unstructured":"Otmani K, Rouas R, Berehab M, Lewalle P (2024) The regulatory mechanisms of oncomiRs in cancer. Biomed Pharmacother 171:116165","journal-title":"Biomed Pharmacother"},{"key":"3898_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2021.10401","volume":"22","author":"L Pan","year":"2021","unstructured":"Pan L, Sha J, Lin W, Wang Y, Bian T, Guo J (2021) Curcumin inhibits prostate cancer progression by regulating the miR-30a-5p\/PCLAF axis. Exp Ther Med 22:1\u20138","journal-title":"Exp Ther Med"},{"key":"3898_CR61","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1111\/cas.15345","volume":"113","author":"S Park","year":"2022","unstructured":"Park S, Kim J, Cho Y, Ahn S, Kim G, Hwang D, Chang Y, Ha S, Choi Y, Lee MH (2022) Promotion of tumorigenesis by miR-1260b\u2013targeting CASP8: potential diagnostic and prognostic marker for breast cancer. Cancer Sci 113:2097\u20132108","journal-title":"Cancer Sci"},{"key":"3898_CR62","unstructured":"Quaye E (2024) Cancer stat facts: Prostate Cancer Statistics. prostate National Cancer Institute. 2024. Accessed June 27. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html"},{"key":"3898_CR63","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41416-021-01677-3","volume":"126","author":"S Rana","year":"2022","unstructured":"Rana S, Valbuena GN, Curry E, Bevan CL, Keun HC (2022) MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data. Br J Cancer 126:502\u2013513","journal-title":"Br J Cancer"},{"issue":"5","key":"3898_CR64","doi-asserted-by":"publisher","first-page":"e26701","DOI":"10.1016\/j.heliyon.2024.e26701","volume":"10","author":"A Rauf","year":"2024","unstructured":"Rauf A, Wilairatana P, Joshi PB, Ahmad Z, Olatunde A, Hafeez N, Hemeg HA, Mubarak MS (2024) Revisiting luteolin: an updated review on its anticancer potential. Heliyon 10(5):e26701","journal-title":"Heliyon"},{"key":"3898_CR65","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10:63","journal-title":"World J Oncol"},{"key":"3898_CR66","doi-asserted-by":"publisher","first-page":"73","DOI":"10.12775\/JEHS.2024.61.005","volume":"61","author":"P Rozwadowska","year":"2024","unstructured":"Rozwadowska P, Bator P, Razik M, Ramian J, Rybak J, Magiera B, Magiera K, Razik W (2024) Anticancer properties of berberine-analysis of the latest reports. J Educ Health Sport 61:73\u201386","journal-title":"J Educ Health Sport"},{"key":"3898_CR67","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ (2017) MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discovery 16:203\u2013222","journal-title":"Nat Rev Drug Discovery"},{"key":"3898_CR68","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/molecules27175730","volume":"27","author":"M Sekhoacha","year":"2022","unstructured":"Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S (2022) Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules 27:5730","journal-title":"Molecules"},{"key":"3898_CR69","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41576-023-00611-y","volume":"24","author":"R Shang","year":"2023","unstructured":"Shang R, Lee S, Senavirathne G, Lai EC (2023) microRNAs in action: biogenesis, function and regulation. Nat Rev Genet 24:816\u2013833","journal-title":"Nat Rev Genet"},{"key":"3898_CR70","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.21037\/tcr-20-1294","volume":"9","author":"PC Sharma","year":"2020","unstructured":"Sharma PC, Gupta A (2020) MicroRNAs: potential biomarkers for diagnosis and prognosis of different cancers. Translational Cancer Research 9:5798","journal-title":"Translational Cancer Research"},{"issue":"1","key":"3898_CR71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2019.90343","volume":"16","author":"H Shen","year":"2020","unstructured":"Shen H, Wang L, Zhang L, Weng X-D, Yang D, Liu X-H (2020) PRMT5, regulated by lncRNA ZFAS1\/miR-150\u20135p, promoted androgen-independent prostate cancer migration and invasion. Arch Med Sci 16(1):1\u201319","journal-title":"Arch Med Sci"},{"key":"3898_CR72","doi-asserted-by":"publisher","first-page":"e51655","DOI":"10.1371\/journal.pone.0051655","volume":"7","author":"S Sheth","year":"2012","unstructured":"Sheth S, Jajoo S, Kaur T, Mukherjea D, Sheehan K, Rybak LP, Ramkumar V (2012) Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt\/MicroRNA-21 pathway. PLoS ONE 7:e51655","journal-title":"PLoS ONE"},{"key":"3898_CR73","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s43088-024-00492-y","volume":"13","author":"SS Shetty","year":"2024","unstructured":"Shetty SS, Shetty S, Kumari NS (2024) Therapeutic efficacy of gut microbiota-derived polyphenol metabolite Urolithin A. Beni-Suef Univ J Basic Appl Sci 13:31","journal-title":"Beni-Suef Univ J Basic Appl Sci"},{"key":"3898_CR74","doi-asserted-by":"publisher","first-page":"603533","DOI":"10.3389\/fonc.2021.603533","volume":"11","author":"H Shi","year":"2021","unstructured":"Shi H, Sun Y, Ruan H, Ji C, Zhang J, Wu P, Li L, Huang C, Jia Y, Zhang X (2021) 3,3\u2032-Diindolylmethane promotes gastric cancer progression via \u03b2-TrCP-mediated NF-\u03baB activation in gastric cancer-derived MSCs. Front Oncol 11:603533","journal-title":"Front Oncol"},{"key":"3898_CR75","doi-asserted-by":"publisher","first-page":"8356","DOI":"10.18632\/oncotarget.14198","volume":"8","author":"M Shiina","year":"2016","unstructured":"Shiina M, Hashimoto Y, Kato T, Yamamura S, Tanaka Y, Majid S, Saini S, Varahram S, Kulkarni P, Dasgupta P (2016) Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African-Americans and Caucasians. Oncotarget 8:8356","journal-title":"Oncotarget"},{"key":"3898_CR76","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1096\/fj.10-167924","volume":"25","author":"IA Siddiqui","year":"2011","unstructured":"Siddiqui IA, Asim M, Hafeez BB, Adhami VM, Tarapore RS, Mukhtar H (2011) Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J 25:1198","journal-title":"FASEB J"},{"key":"3898_CR77","doi-asserted-by":"crossref","unstructured":"Singh VK, Rajak N, Singh Y, Singh AK, Giri R, Garg N (2024) Role of MicroRNA-21 in prostate cancer progression and metastasis: molecular mechanisms to therapeutic targets. Ann Surg Oncol 1\u201314","DOI":"10.1245\/s10434-024-15453-z"},{"key":"3898_CR78","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3390\/molecules29061373","volume":"29","author":"WH Talib","year":"2024","unstructured":"Talib WH, Awajan D, Alqudah A, Alsawwaf R, Althunibat R, Abu AlRoos M, Al Safadi A, Abu Asab S, Hadi RW, Al Kury LT (2024) Targeting cancer hallmarks with epigallocatechin gallate (EGCG): mechanistic basis and therapeutic targets. Molecules 29:1373","journal-title":"Molecules"},{"key":"3898_CR79","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.3390\/biom10111536","volume":"10","author":"D Termini","year":"2020","unstructured":"Termini D, Den Hartogh DJ, Jaglanian A, Tsiani E (2020) Curcumin against prostate cancer: current evidence. Biomolecules 10:1536","journal-title":"Biomolecules"},{"key":"3898_CR80","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.fct.2018.11.041","volume":"123","author":"D Tewari","year":"2019","unstructured":"Tewari D, Rawat P, Singh PK (2019) Adverse drug reactions of anticancer drugs derived from natural sources. Food Chem Toxicol 123:522\u2013535","journal-title":"Food Chem Toxicol"},{"key":"3898_CR81","doi-asserted-by":"publisher","first-page":"101596","DOI":"10.1016\/j.tranon.2022.101596","volume":"27","author":"HS Tuli","year":"2023","unstructured":"Tuli HS, Garg VK, Bhushan S, Uttam V, Sharma U, Jain A, Sak K, Yadav V, Lorenzo JM, Dhama K (2023) Natural flavonoids exhibit potent anticancer activity by targeting microRNAs in cancer: a signature step hinting towards clinical perfection. Translational Oncology 27:101596","journal-title":"Translational Oncology"},{"key":"3898_CR82","doi-asserted-by":"crossref","unstructured":"Uzuner E, Ulu GT, G\u00fcrler SB, Baran Y (2022) The role of MiRNA in cancer: pathogenesis, diagnosis, and treatment. miRNomics: MicroRNA Biol Comput Anal 375\u2013422","DOI":"10.1007\/978-1-0716-1170-8_18"},{"key":"3898_CR83","doi-asserted-by":"publisher","first-page":"e43511","DOI":"10.7554\/eLife.43511","volume":"8","author":"X Yan","year":"2019","unstructured":"Yan X, Tang B, Chen B, Shan Y, Yang H (2019) Replication study: the microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Elife 8:e43511","journal-title":"Elife"},{"key":"3898_CR84","doi-asserted-by":"publisher","first-page":"9688","DOI":"10.1093\/nar\/gkt680","volume":"41","author":"X Yang","year":"2013","unstructured":"Yang X, Du WW, Li H, Liu F, Khorshidi A, Rutnam ZJ, Yang BB (2013) Both mature miR-17-5p and passenger strand miR-17-3p target TIMP3 and induce prostate tumor growth and invasion. Nucleic Acids Res 41:9688\u20139704","journal-title":"Nucleic Acids Res"},{"key":"3898_CR85","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/1940-6207.CAPR-13-0032","volume":"6","author":"B Yi","year":"2013","unstructured":"Yi B, Piazza GA, Su X, Xi Y (2013) MicroRNA and cancer chemoprevention. Cancer Prev Res 6:401\u2013409","journal-title":"Cancer Prev Res"},{"key":"3898_CR86","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.abb.2018.07.010","volume":"654","author":"J Yu","year":"2018","unstructured":"Yu J, Feng Y, Wang Y, An R (2018) Aryl hydrocarbon receptor enhances the expression of miR-150-5p to suppress in prostate cancer progression by regulating MAP3K12. Arch Biochem Biophys 654:47\u201354","journal-title":"Arch Biochem Biophys"},{"key":"3898_CR87","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s12672-024-01376-4","volume":"15","author":"F Yuan","year":"2024","unstructured":"Yuan F, Hu Y, Lei Y, Jin L (2024) Recent progress in microRNA research for prostate cancer. Discover Oncol 15:480","journal-title":"Discover Oncol"},{"key":"3898_CR88","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s10555-012-9368-6","volume":"31","author":"J Zhang","year":"2012","unstructured":"Zhang J, Ma L (2012) MicroRNA control of epithelial-mesenchymal transition and metastasis. Cancer Metastasis Rev 31:653\u2013662","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"3898_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/atm.2019.02.40","volume":"7","author":"J Zhang","year":"2019","unstructured":"Zhang J, Zhang H, Qin Y, Chen C, Yang J, Song N, Gu M (2019) MicroRNA-200c-3p\/ZEB2 loop plays a crucial role in the tumor progression of prostate carcinoma. Ann Transl Med 7(7):1\u201313","journal-title":"Ann Transl Med"},{"key":"3898_CR90","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/21691401.2018.1553783","volume":"47","author":"H Zhao","year":"2019","unstructured":"Zhao H, Zhang W, Lai X, Zhu H, Zhang S, Wu W, Wang S, Tang M, Deng Z, Tan J (2019) MiR-30a-5p frequently downregulated in prostate cancer inhibits cell proliferation via targeting PCLAF. Artif Cells, Nanomed Biotechnol 47:278\u2013289","journal-title":"Artif Cells, Nanomed Biotechnol"},{"key":"3898_CR91","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.fct.2016.10.005","volume":"97","author":"B Zhou","year":"2016","unstructured":"Zhou B, Wang J, Zheng G, Qiu Z (2016a) Methylated urolithin A, the modified ellagitannin-derived metabolite, suppresses cell viability of DU145 human prostate cancer cells via targeting miR-21. Food Chem Toxicol 97:375\u2013384","journal-title":"Food Chem Toxicol"},{"key":"3898_CR92","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.3892\/ijo.2016.3392","volume":"48","author":"P Zhou","year":"2016","unstructured":"Zhou P, Ma L, Zhou J, Jiang M, Rao E, Zhao Y, Guo F (2016b) miR-17-92 plays an oncogenic role and conveys chemo-resistance to cisplatin in human prostate cancer cells. Int J Oncol 48:1737\u20131748","journal-title":"Int J Oncol"},{"key":"3898_CR93","doi-asserted-by":"publisher","first-page":"15616","DOI":"10.1002\/jcb.28828","volume":"120","author":"M Zhu","year":"2019","unstructured":"Zhu M, Zheng Z, Huang J, Ma X, Huang C, Wu R, Li X, Liang Z, Deng F, Wu J (2019) Modulation of miR-34a in curcumin-induced antiproliferation of prostate cancer cells. J Cell Biochem 120:15616\u201315624","journal-title":"J Cell Biochem"},{"key":"3898_CR94","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3390\/biomedicines10020312","volume":"10","author":"V Zoi","year":"2022","unstructured":"Zoi V, Galani V, Tsekeris P, Kyritsis AP, Alexiou GA (2022) Radiosensitization and radioprotection by curcumin in glioblastoma and other cancers. Biomedicines 10:312","journal-title":"Biomedicines"},{"key":"3898_CR95","doi-asserted-by":"publisher","first-page":"1348076","DOI":"10.3389\/fphar.2024.1348076","volume":"15","author":"J-Y Zou","year":"2024","unstructured":"Zou J-Y, Chen Q-L, Luo X-C, Damdinjav D, Abdelmohsen UR, Li H-Y, Battulga T, Chen H-B, Wang Y-Q, Zhang J-Y (2024) Natural products reverse cancer multidrug resistance. Front Pharmacol 15:1348076","journal-title":"Front Pharmacol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03898-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-03898-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03898-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T07:24:56Z","timestamp":1757143496000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-03898-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":95,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3898"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-03898-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"28 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}